Cargando…

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses f...

Descripción completa

Detalles Bibliográficos
Autores principales: van Rijswijck, Danique M. H., Bondt, Albert, Hoek, Max, van der Straten, Karlijn, Caniels, Tom G., Poniman, Meliawati, Eggink, Dirk, Reusken, Chantal, de Bree, Godelieve J., Sanders, Rogier W., van Gils, Marit J., Heck, Albert J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568977/
https://www.ncbi.nlm.nih.gov/pubmed/36243713
http://dx.doi.org/10.1038/s41467-022-33899-1
_version_ 1784809763642540032
author van Rijswijck, Danique M. H.
Bondt, Albert
Hoek, Max
van der Straten, Karlijn
Caniels, Tom G.
Poniman, Meliawati
Eggink, Dirk
Reusken, Chantal
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
Heck, Albert J. R.
author_facet van Rijswijck, Danique M. H.
Bondt, Albert
Hoek, Max
van der Straten, Karlijn
Caniels, Tom G.
Poniman, Meliawati
Eggink, Dirk
Reusken, Chantal
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
Heck, Albert J. R.
author_sort van Rijswijck, Danique M. H.
collection PubMed
description Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases.
format Online
Article
Text
id pubmed-9568977
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95689772022-10-16 Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern van Rijswijck, Danique M. H. Bondt, Albert Hoek, Max van der Straten, Karlijn Caniels, Tom G. Poniman, Meliawati Eggink, Dirk Reusken, Chantal de Bree, Godelieve J. Sanders, Rogier W. van Gils, Marit J. Heck, Albert J. R. Nat Commun Article Existing assays to measure antibody cross-reactivity against different SARS-CoV-2 spike (S) protein variants lack the discriminatory power to provide insights at the level of individual clones. Using a mass spectrometry-based approach we are able to monitor individual donors’ IgG1 clonal responses following a SARS-CoV-2 infection. We monitor the plasma clonal IgG1 profiles of 8 donors who had experienced an infection by either the wild type Wuhan Hu-1 virus or one of 3 VOCs (Alpha, Beta and Gamma). In these donors we chart the full plasma IgG1 repertoires as well as the IgG1 repertoires targeting the SARS-CoV-2 spike protein trimer VOC antigens. The plasma of each donor contains numerous anti-spike IgG1 antibodies, accounting for <0.1% up to almost 10% of all IgG1s. Some of these antibodies are VOC-specific whereas others do recognize multiple or even all VOCs. We show that in these polyclonal responses, each clone exhibits a distinct cross-reactivity and also distinct virus neutralization capacity. These observations support the need for a more personalized look at the antibody clonal responses to infectious diseases. Nature Publishing Group UK 2022-10-15 /pmc/articles/PMC9568977/ /pubmed/36243713 http://dx.doi.org/10.1038/s41467-022-33899-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
van Rijswijck, Danique M. H.
Bondt, Albert
Hoek, Max
van der Straten, Karlijn
Caniels, Tom G.
Poniman, Meliawati
Eggink, Dirk
Reusken, Chantal
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
Heck, Albert J. R.
Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title_full Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title_fullStr Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title_full_unstemmed Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title_short Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
title_sort discriminating cross-reactivity in polyclonal igg1 responses against sars-cov-2 variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568977/
https://www.ncbi.nlm.nih.gov/pubmed/36243713
http://dx.doi.org/10.1038/s41467-022-33899-1
work_keys_str_mv AT vanrijswijckdaniquemh discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT bondtalbert discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT hoekmax discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT vanderstratenkarlijn discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT canielstomg discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT ponimanmeliawati discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT egginkdirk discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT reuskenchantal discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT debreegodelievej discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT sandersrogierw discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT vangilsmaritj discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern
AT heckalbertjr discriminatingcrossreactivityinpolyclonaligg1responsesagainstsarscov2variantsofconcern